FDA approves revised labeling for Thrombin-JMI.
Enhanced processes to reduce Factor V light chain content to undetectable levels during the manufacture of
Q&A: How Specific GLP-1s Impact Different Patient Populations | ASHP Midyear
Jennifer Clements, PharmD, BCACP, BC-ADM, BCPS, CDCES, FADCES, FCCP, discussed current GLP-1 medication offerings and how each impacts patients differently.